Ozempic Gastroparesis Settlement Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Drug Safety Analysis

The legacy domain of general health and science information has historically provided broad, accessible overviews of medical conditions, treatments, and public health guidance. This foundation served to educate a wide audience on fundamental health topics, from disease prevention to therapeutic options. Within this context, discussions of metabolic health and diabetes management have long been central, covering lifestyle interventions and pharmacological advances. As the informational landscape evolves, a more targeted focus emerges: the intersection of widely prescribed medications and specific adverse outcomes. One such area of growing attention involves glucagon-like peptide-1 receptor agonists, a class of drugs originally developed for glycemic control. Their expanded use has prompted closer scrutiny of potential gastrointestinal effects, particularly in populations with prolonged exposure. This shift from general health education to a concentrated examination of drug safety signals represents a natural progression. The present inquiry narrows the lens to a specific concern: the relationship between Ozempic exposure and the development of gastroparesis. Understanding the criteria for related settlements requires moving beyond broad health principles to assess real-world exposure patterns and reported complications, thereby bridging general awareness with a focused risk evaluation.

Find Out If You Qualify for Compensation →

Bridging General Awareness with Ozempic-Specific Risk Evaluation

Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism of action involves slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. Clinical trial data demonstrate that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Link Between Ozempic and Gastroparesis

These adverse effects are consistent with the known pharmacology of GLP-1 receptor agonists, which delay gastric emptying and can exacerbate or unmask gastroparesis in susceptible individuals. The mechanistic pathway linking Ozempic to gastroparesis involves its action on GLP-1 receptors in the gastrointestinal tract, which slows gastric motility. This can lead to symptoms that overlap with gastroparesis, such as nausea, vomiting, and early satiety. In patients with pre-existing delayed gastric emptying or those who develop severe symptoms, prolonged use may result in clinically significant gastroparesis. The timeline between exposure and documented harm varies; symptoms often emerge during dose escalation, as noted in clinical trials where the majority of gastrointestinal adverse reactions occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, some patients may experience delayed onset after months of treatment. Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions in the label, but does not specifically mention gastroparesis as a distinct adverse event. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other antidiabetic therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). There is no explicit warning about gastroparesis, which may be relevant for patients with pre-existing gastric motility disorders or those who develop severe gastrointestinal symptoms. This gap in labeling could be a factor in settlement considerations for affected patients.

Settlement Criteria for Ozempic-Related Gastroparesis

Settlement-related considerations for patients who develop gastroparesis after Ozempic use typically involve documenting the timeline between exposure and symptom onset, confirming the diagnosis through objective testing (e.g., gastric emptying studies), and establishing that the harm is attributable to the medication rather than other causes. Patients may need to demonstrate that they experienced severe or persistent gastrointestinal symptoms leading to discontinuation, as seen in clinical trial data where 3.1% to 3.8% of patients discontinued due to gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Legal criteria for settlements often require evidence that the manufacturer failed to adequately warn about the risk of gastroparesis, and that the patient suffered documented harm within a reasonable timeframe after exposure. In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, including those that can mimic or cause gastroparesis. Clinical trial data show dose-dependent increases in gastrointestinal adverse events, with higher rates at 2 mg compared to 1 mg. The label does not specifically warn about gastroparesis, which may be relevant for patients who develop severe symptoms. Settlement criteria for affected patients typically require documented harm, a clear timeline of exposure, and evidence of inadequate warnings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism of action, which can cause or exacerbate gastroparesis symptoms such as nausea, vomiting, and early satiety. Clinical trials show dose-dependent increases in gastrointestinal adverse reactions, with rates up to 36.4% at 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic-induced gastroparesis?

Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis via objective testing (e.g., gastric emptying scintigraphy), a clear timeline linking exposure to symptom onset, evidence of severe or persistent symptoms leading to discontinuation, and proof that the manufacturer failed to adequately warn about the risk of gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.